The Medical Genome Initiative is a consortium founded by leading institutions with significant interest and experience in evaluating human genomes for the genetic basis of diseases.
We believe early utilization of clinical whole genome sequencing (cWGS) has the potential to deliver precise molecular diagnosis to enable change in medical management, thereby reducing the number of unresolved, complex, costly and chronic genetic disease cases, especially for newborns and children.
Our initial goal is to publish recommended laboratory and clinical best practices for the implementation of cWGS, as well as common clinical research frameworks for demonstrating the value cWGS brings to healthcare.
Clinical Whole Genome Sequencing
Clinical whole genome sequencing (cWGS) is the laboratory process of sequencing all 3 billion base pairs in the human genome to identify a disease-causing mutation. Emerging evidence shows cWGS can detect most forms of clinically relevant variation for patients with a rare genetic disease1. cWGS has the potential to reduce the number of unresolved pediatric rare genetic disease cases, especially when utilized as a first-tier clinical test, eliminating the traditional lengthy and costly stepwise approach to genetic testing.
Medical Genome Initiative Consortium Members
Steering Committee Members
- Hutton Kearney, PhD, Mayo Clinic
- Shashikant Kulkarni, PhD, Baylor Genetics & Baylor College of Medicine
- Euan Ashley, MD, PhD, Stanford Medicine
- David Dimmock, MD, Rady Children’s Institute for Genomic Medicine
- (Chairperson) Christian Marshall, PhD, The Hospital for Sick Children (SickKids)
- Heidi Rehm, PhD, The Broad Institute
- David Bick, MD, HudsonAlpha Institute for Biotechnology
- John Belmont, MD, PhD, Illumina
Best Practices for Applying cWGS in Rare, Undiagnosed, and Genetic Diseases
Learn more about The Medical Genome Initiative and get answers to your questions.
The Medical Genome Initiative ©2019. All Rights Reserved.